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  Background:  Intrathecal (IT) magnesium has antinociceptive effects on animals and has been reported to prolong spinal opioid 
analgesia in humans.  This study examined the effect of IT magnesium on spinal anesthesia and postoperative epidural analgesia.
  Methods:  Sixty patients undergoing total knee replacement were enrolled in this study.  Before the IT injection of 0.5% isobaric 
tetracaine (10 mg), group C and group M received 0.9% saline or 50% magnesium sulfate 0.1 ml, respectively.  The epidural 
solution for postoperative analgesia contained 0.2% ropivacaine (100 ml) only in group M, and 0.2% ropivacaine plus morphine 
(50μg/ml) in group C.  The verbal rating scale (VRS) scores for pain, sensory block level, intensity of motor block and side 
effects were recorded at 5, 60, and 120 minutes after the IT injection and at 1, 12 and 36 hours after surgery in the post-anesthesia 
care unit (PACU).
  Results:  The VRS score at 120 minutes after the IT injection were lower in group M than in group C (P ＜ 0.05).  There 
were no differences in the VRS scores and the use of supplemental analgesics at the postoperative period.  The incidence of 
PONV, pruritus and urinary retention was significantly lower in group M than in group C at 12 and 36 hours after surgery.
  Conclusions:  IT magnesium can be used as a local anesthetic adjuvant to strengthen the analgesic effect of spinal local anesthesia 
and to intensify the analgesic effect of epidural local anesthesia for postoperative pain control to the extent of 5 mg epidural 
morphine.  (Korean J Anesthesiol 2007; 52: S 72～6)
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INTRODUCTION
  Magnesium is the fourth most abundant cation in the body 
and the second most abundant intracellular cation. It has nu-
merous physiological activities including activation of enzymes 
involved in energy metabolism, protein synthesis, regulation of 
vasomotor tone, neurotransmission and signaling.1,2) Magnesium 
sulfate (MgSO4) has been used as a pharmacological agent in 
a variety of clinical situations such as tachyarrythmia, myocar-
dial and neuronal ischemia, asthma, and seizures in preeclamp-
sia.3) Magnesium also has antinociceptive effects in animal and 
human pain models.3-5) These effects are primarily based on 
the regulation of calcium influx into the cell, natural physiolo-
gic calcium antagonism,2) and antagonism of the N-methyl-D- 
aspartate (NMDA) receptor.6)
  Although some clinical reports3,4) have demonstrated antino-
ciceptive effects of systemically administered MgSO4, results 
are not consistent.7,8) There are considerable evidences that in-
trathecally administered magnesium has antinociceptive effects 
in animals.5,9,10) In addition, the safety profile has been eval-
uated, including histopathological analysis.11) In the first ran-
domized human study of intrathecal (IT) magnesium as an 
antinociceptive modulator, the addition of IT magnesium, acting 
as a noncompetitive NMDA antagonist, has shown prolongation 
of the analgesic effect of opioids in spinal analgesia.12) Magne-
sium has also been shown to potentiate the analgesic effect of 
bupivacaine when co-administered intrathecally in rats.13) However, 
no clinical study has examined the effect of IT MgSO4 with 
local anesthetics in humans.
  We therefore conducted a prospective, randomized, controlled 
clinical trial to investigate the effect of intrathecally co-admin-
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Table 1. Patient Characteristics and Duration of Surgery
󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚
Group C Group M
(n = 30) (n = 30)
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
Sex (M/F)   2/28  1/29
Age (yr) 66.2 ± 5.7 67.8 ± 7.3
Height (cm) 154.9 ± 6.8 153.9 ± 4.9
Weight (kg) 64.3 ± 8.0 58.4 ± 10.0
Duration of surgery (min) 78.5 ± 18.5 76.9 ± 21.0
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
Values are mean ± SD except sex, which are number of patients. 
Group C: patients receive 0.5% isobaric tetracaine (10 mg) with 0.9% 
saline (0.1 ml) intrathecally and then patient controlled epidural 
analgesia (PCEA) with 0.2% ropivacaine plus morphine (50μg/ml) 
for postoperative analgesia, Group M: patients receive 0.5% isobaric 
tetracaine (10 mg) with 50% magnesium sulfate (0.1 ml, 50 mg) 
intrathecally and then PCEA with 0.2% ropivacaine only for pos-
toperative analgesia.
istered magnesium and local anesthetics on the intensity, block 
level, and duration of spinal anesthesia, and the epidural local 
anesthetics intensifying effect of IT magnesium on postoper-
ative epidural analgesia in patients undergoing total knee re-
placement (TKR).
MATERIALS AND METHODS
  The hospital ethics committee approved this study and in-
formed consent was obtained from all patients. Sixty patients 
with ASA physical status 1 and 2 undergoing elective TKR 
were included. All combined spinal-epidural (CSE) procedures 
were done by the same experienced anesthesiologist. All pa-
tients underwent TKR by the same surgeon.
  Patient characteristics and duration of surgery were compa-
rable between the groups (Table 1).
  Patients were excluded from participation for any contraindi-
cation to regional anesthesia, a history of opioid medication or 
magnesium treatment, allergy to morphine, magnesium and lo-
cal anesthetics, or significant coexisting diseases (hepatic, renal 
or cardiovascular diseases). Patients were randomized using a 
sealed envelope system to receive IT MgSO4 or IT placebo. 
Each group contained 30 patients. Before surgery, patients 
were instructed on the use of the patient controlled epidural 
analgesia (PCEA) device and the VRS (verbal rating scale) for 
pain assessment.
  Patients received 500-1,000 ml of intravenous balanced salt 
solution and were placed in left lateral position for a CSE 
procedure. An 18-gauge Tuohy needle, 8.89 cm (Portex, New 
Hampshire, USA) was introduced via a midline approach into 
the L3-4 vertebral level epidural space using loss of resis-
tance technique. A 27-gauge, 11.9 cm Whitacre tip spinal nee-
dle was placed through the Tuohy needle, and subarachnoid 
placement was confirmed by free flow of cerebrospinal fluid.
  Patients and anesthesia providers were blinded to the treat-
ment group and an independent researcher prepared the first 
study solution containing 0.1 ml of 0.9% saline for group C 
or preservative free-50% magnesium sulfate (50 mg, Masi 50%Ⓡ, 
Huons, Seoul, Korea) for group M. Prior to IT injection of 2 ml 
(10 mg) 0.5% isobaric tetracaine (PantocainsterileⓇ, Daihan 
Pharm., Seoul, Korea), first study solution was given. The spi-
nal needle was removed and a 20-gauge, closed end, multiport 
catheter was inserted 4-5 cm cephalad within the epidural 
space, and the patient was placed in supine position. Electro-
cardiogram and arterial oxygen saturation were monitored con-
tinuously and the non-invasive blood pressure was recorded 
every 5 minutes until the end of the surgical procedure, and 
then every 10 minutes until recovery. Intravenous crystalloids, 
or colloids, and small doses of ephedrine were used to main-
tain mean arterial pressure within 20% of baseline. If the pa-
tient complained of pain during surgery, a 5-7 ml bolus of 
supplemental 2% lidocaine was administered via the epidural 
catheter.
  Scores for pain, upper level of loss of cold sensation, 
intensity of motor block, and somnolence were recorded at 5, 
60, and 120 minutes after the IT injection. Pain level was 
assessed by VRS scores scaled from 0 to 10 (0 = no pain, 10 
= the worst pain imagined). The upper level of loss of cold 
sensation was assessed at the midclavicular line using an alco-
hol swab bilaterally. The intensity of motor block was graded 
as 0 (none) = full flexion of knees and feet; 1 (partial) = just 
able to move knees; 2 (almost complete) = able to move feet 
only; and 3 (complete) = unable to move feet or knees. Som-
nolence was categorized as 1 = fully awake; 2 = somnolent 
and responds to call; 3 = somnolent and no response to verbal 
stimulation; and 4 = asleep and responds to only painful stim-
ulation.12)
  In the postanesthesia care unit (PACU) epidural analgesia 
was started using the PCEA technique with silicone balloon in-
fuser (Accufuser PlusⓇ, Woo Young Med., Paju, Korea) con-
taining the second study solution made by the researcher who 
prepared the first study solution, after parameters 120 minutes 
post-IT injection were checked. The second study solution 
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Table 2. Pain Scores, Upper Sensory Level, Intensity of Motor 
Block and Somnolence Score
󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚
Elapsed time Group C Group M
from spinal anesthesia (n = 30) (n = 30)
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
5 min 0 0
VRS 60 min 0 0
120 min 1.7 ± 2.9 0*
Upper sensory level 5 min T7 (T3-12) T8 (T4-L1)
60 min T6 (T3-12) T6 (T3-12)
120 min T6 (T4-12) T6 (T3-12)
Motor block 5 min 2.7 ± 0.6 2.5 ± 0.6
60 min 3.0 ± 0.0 2.9 ± 0.4
120 min 3.0 ± 0.0 3.0 ± 0.0
Somnolence score 5 min 1.0 ± 0.2 1.0 ± 0.2
60 min 1.3 ± 0.5 1.4 ± 0.6
120 min 1.0 ± 0.0 1.1 ± 0.4
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
Values are mean ± SD, except for upper sensory level, which 
are median (range). VRS: verbal rating scale, Group C: patients 
receive 0.5% isobaric tetracaine (10 mg) with 0.9% saline (0.1 ml) 
intrathecally and then patient controlled epidural analgesia (PCEA) 
with 0.2% ropivacaine plus morphine (50μg/ml) for postoperative 
analgesia, Group M: patients receive 0.5% isobaric tetracaine (10 mg) 
with 50% magnesium sulfate (0.1 ml, 50 mg) intrathecally and 
then PCEA with 0.2% ropivacaine only for postoperative an-
algesia. *P ＜ 0.05 compared with group C.
Table 3. Pain Scores and Number of Rescue Analgesia in Post-
operative Period
󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚
Postoperative Group C Group M
period (n = 30) (n = 30)
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
at PACU 0.1 ± 0.7 0.1 ± 0.6
VRSR 12 hr 5.0 ± 3.4 3.7 ± 3.0
36 hr 4.1 ± 2.4 4.3 ± 2.5
VRSM 12 hr 6.0 ± 3.0 6.5 ± 2.4
36 hr 7.2 ± 2.4 6.9 ± 2.1
No. of rescue analgesia at PACU 0.7 ± 0.6 0.9 ± 0.8
  per each patient 12 hr 0.5 ± 0.8 0.4 ± 0.6
36 hr 0.4 ± 0.7 0.2 ± 0.5
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
Values are mean ± SD. VRSR: verbal rating scale at rest, PACU: 
postanesthesia care unit, VRSM: verbal rating scale on movement, 
No. of rescue analgesia; frequency of rescue analgesia (25 mg 
meperidine, IM). Group C: patients receive 0.5% isobaric tetra-
caine (10 mg) with 0.9% saline (0.1 ml) intrathecally and then 
patient controlled epidural analgesia (PCEA) with 0.2% ropivacaine 
plus morphine (50μg/ml) for postoperative analgesia, Group M: 
patients receive 0.5% isobaric tetracaine (10 mg) with 50% magne-
sium sulfate (0.1 ml, 50 mg) intrathecally and then PCEA with 
0.2% ropivacaine only for postoperative analgesia.
consisted of 0.2% ropivacaine mixed, with morphine sulfate 5 
mg (50μg/ml) in group C and 0.5 ml normal saline in group 
M. Balloon pump infuser setting included 2 ml/hr for con-
tinuous infusion and 0.5 ml for bolus dose with a 15 minutes 
lockout period for postoperative 36 hours. Patients with VRS 
score higher than 5 were given meperidine 25 mg intramus-
cular (IM) as rescue analgesia. Each patient was interviewed at 
1 hour after arrival on PACU, at 12, and 36 hours post-oper-
ation by an investigator blinded to patient group. Pain intensity 
at rest and on the operated leg movement by VRS scores, the 
occurrence of postoperative nausea and vomiting (PONV), pru-
ritus, urinary retention and somnolence were assessed. The pre-
sence of motor or sensory complications was assessed 6 weeks 
after TKR as a routine postoperative evaluation by the surgeon 
who was blind to the study group. 
  Preliminary study indicated that with 30 patients per group, 
the study would have a 90% chance (β = 0.9) of detecting a 
difference, at a 5% level of significance, of at least 1.6 VRS 
score at 120 minutes after IT injection.
  Statistical analysis was performed using the statistical pack-
age for social sciences statistical software (SPSS 10.0, USA). 
Demographic data were compared using the unpaired t-test. 
The VRS score, sensory level, motor score and somnolence 
score were analyzed using the Mann-Whitney U-test. The 
incidence of post-operative adverse events was analyzed using 
Fisher's exact test. Results are expressed as mean ± SD, 
median (range) or number of patients. A P value of less than 
0.05 was considered statistically significant. 
RESULTS
  The VRS scores at 120 minutes after IT injection were sig-
nificantly lower in group M than group C (P ＜ 0.05)(Table 2). 
All group M patients reported lasting analgesic effects up to 
120 minutes after IT injection. Intraoperative supplemental 2% 
lidocaine was requested via the epidural catheter in only one 
patient of group C.
  There were no differences in the VRS scores at rest and on 
movement and in supplemental analgesic use between two groups 
at PACU, 12, and 36 hours post-operation (Table 3). The in-
fuser became empty, which took average time of 43.4 ± 6.3 
hrs in group M and 43.3 ± 5.4 hrs in group C. There was 
no significant difference between the two groups.
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Table 4. Postoperative Side Effects
󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚
Postoperative Group C Group M
period (n = 30) (n = 30)
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
Nausea (%) at PACU 3.3 6.7
12 hr 60.0 16.7*
36 hr 40.0 10.0*
Vomiting (%) at PACU 0 0
12 hr 40.0 10.0*
36 hr 10.0 0*
Pruritus (%) at PACU 0 0
12 hr 66.7 10.0*
36 hr 33.1 16.7*
Urinary retention (%) at PACU 0 0
12 hr 16.7 6.7*
36 hr 13.3 0*
Somnolence (%) at PACU 3.3 3.3
12 hr 0 0
36 hr 3.3 0
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
Values are the percentage of patients. PACU: postanesthesia care 
unit. Group C: patients receive 0.5% isobaric tetracaine (10 mg) 
with 0.9% saline (0.1 ml) intrathecally and then patient controlled 
epidural analgesia (PCEA) with 0.2% ropivacaine plus morphine 
(50μg/ml) for postoperative analgesia, Group M: patients receive 
0.5% isobaric tetracaine (10 mg) with 50% magnesium sulfate (0.1 
ml, 50 mg) intrathecally and then PCEA with 0.2% ropivacaine 
only for postoperative analgesia. *P ＜ 0.05 compared with group C.
  At 12 and 36 hours post-operation, PONV, pruritus and uri-
nary retention incidence was significantly lower in group M 
than group C (P ＜ 0.05)(Table 4). There was no significant 
difference between two groups in incidence of somnolence dur-
ing the whole study period.
  No patient in either group had any sensory or motor com-
plication on routine postoperative evaluation 6 weeks after TKR.
DISCUSSION
  This study demonstrated that 50 mg of IT magnesium, as a 
noncompetitive NMDA antagonist, improved spinal analgesic 
effect of local anesthetic up to 2 hours. Even though group M 
PCEA solution contained only local anesthetic agent whereas 
group C PCEA solution was added morphine, there was no 
difference in the intensity of postoperative epidural analgesia 
between the two groups.
  At doses used in this study, intrathecally administered MgSO4 
has been reported to prolong the duration of spinal opioid an-
algesia without increasing adverse events in parturiants.12) In 
this previous human study, the dose of magnesium was based 
on data from a rat model of postoperative pain in which mor-
phine antinociception was potentiated with 188μg of IT mag-
nesium.10) Based on the relative differences in CSF volume and 
body weight between human and rat, the 188μg was conser-
vatively extrapolated to 50 mg. In rats, repeated IT injections 
of 9.2 mg/kg iso-osmolar MgSO4 produced transient motor and 
sensory block similar to that of 2% lidocaine with complete 
recovery and benign clinical consequences.11) In a canine study, 
3 mg/kg (45-60 mg) IT MgSO4 before thoracic aortic cross- 
clamping did not produce neurological deficit or spinal cord 
abnormalities whereas adverse neurological outcome and an is-
chemic-injury pattern on histopathological examination were seen 
in control group.14) If the 45-60 mg IT magnesium dose 
which is protective of the spinal cord in dogs were extrap-
olated by comparing the relative CSF volumes (approximately 
12 ml versus 120 ml), this represent a 450-650 mg dose in 
human. Comparatively, the dosage of IT magnesium used in 
this study is 10% of a dose shown to be nontoxic in dogs. 
Lejuste15) described the inadvertent IT injection of 1,000 mg of 
magnesium, producing a dense motor block followed by 
complete resolution within 90 minutes, with no neurological 
deficit at long-term follow-up.
  Other various intrathecal adjuvants such as NMDA antago-
nists, clonidine, and neostigmine have been assessed as possi-
bilities for improved pain relief without side effects.16-18) Of 
these, magnesium, as calcium antagonist and NMDA receptor 
blocker, has also the promising antinociceptive effects.2,6)
  In the previous clinical studies, the perioperative intravenous 
(IV) administration of MgSO4 has shown the equivocal results. 
Some clinical studies have demonstrated antinociceptive effects 
for systemically administered MgSO4 on the assumption that 
magnesium acts on NMDA receptors located in the spinal cord.3,4) 
Whereas, no decrease in postoperative analgesic consumption 
was observed in a randomized clinical trial using IV mag-
nesium (bolus and infusion). IV magnesium for modulation of 
antinociception via NMDA channel antagonism is insufficient 
blood-brain barrier penetration to achieve effective CSF con-
centration.8,19) Considering these factors, recent studies have 
focused on the antinociceptive effect of IT magnesium.9,10,12) 
  According to the human study of IT magnesium, conducted 
in labor analgesia, the median analgesic duration of 25μg fen-
tanyl was 60 minutes, which was prolonged to 75 minutes with 
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addition of 50 mg IT magnesium.12) Perioperative application 
of IV magnesium has been reported to reduce morphine con-
sumption during the first 48 hours after surgery in patients 
undergoing abdominal hysterectomy with general anesthesia.3) 
According to the results of this study, IT magnesium 
performed more dense sensory block up to 120 minutes. There 
were no differences in the VAS scores and additional acquired 
analgesics between group M and group C for the whole study 
period. Initially, the control group was designed to receive 
only local anesthetics via PCEA and IT normal saline prior to 
0.5% tetracaine of spinal anesthesia. However, VAS at resting 
on postoperative 12 hr was 7.9 ± 0.9 in control group, in 
contrast with 3.7 ± 3.0 in group M. In addition, 4 of 6 in 
control group refused the epidural solution. Because of this 
intractable pain, we discarded the initially designed control 
group. After then, morphine was added to PCEA (group C). 
We could not differentiate whether these results were induced 
by either prolongation of spinal local anesthetics or some 
preemptive analgesic effect due to IT magnesium as an 
NMDA receptor antagonist. However, we obviously 
demonstrated that single IT magnesium might be as effective 
as postoperative epidural morphine 5 mg during the whole 
study period.
  This study is limited by the use of a long acting spinal an-
esthetic, so it may have overshadowed any true analgesic be-
nefits of IT magnesium. To evaluate the effect of IT magne-
sium as adjuvants of spinal local anesthetics, it would have 
been helpful to test patients until complete regression of spinal 
anesthetic with the more frequent interval.
  In conclusion, IT magnesium co-administered with local an-
esthetics, both strengthened the analgesic effects of the intra-
operative spinal local anesthetics, and postoperative epidural an-
algesia. IT magnesium might be considered as a local anes-
thetic adjuvant and to intensify postoperative epidural local an-
esthetics.
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